<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36737740</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis: a Mendelian randomization study.</ArticleTitle><Pagination><StartPage>39</StartPage><MedlinePgn>39</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">39</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-023-02736-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that is accompanied by muscle weakness and muscle atrophy, typically resulting in death within 3-5 years from the disease occurrence. Though the cause of ALS remains unclear, increasing evidence has suggested that inflammation is involved in the pathogenesis of ALS. Thus, we performed two-sample Mendelian randomization (MR) analyses to estimate the associations of circulating levels of cytokines and growth factors with the risk of ALS.</AbstractText><AbstractText Label="METHODS">Genetic instrumental variables for circulating cytokines and growth factors were identified from a genome-wide association study (GWAS) of 8293 European participants. Summary statistics of ALS were obtained from a GWAS including 20,806 ALS cases and 59,804 controls of European ancestry. We used the inverse-variance weighted (IVW) method as the primary analysis. To test the robustness of our results, we further performed the simple-median method, weighted-median method, MR-Egger regression, and MR pleiotropy residual sum and outlier test. Finally, a reverse MR analysis was performed to assess the possibility of reverse causation between ALS and the cytokines that we identified.</AbstractText><AbstractText Label="RESULTS">After Bonferroni correction, genetically predicted circulating level of basic fibroblast growth factor (FGF-basic) was suggestively associated with a lower risk of ALS [odds ratio (OR): 0.74, 95% confidence interval (95% CI): 0.60-0.92, P = 0.007]. We also observed suggestive evidence that interferon gamma-induced protein 10 (IP-10) was associated with a 10% higher risk of ALS (OR: 1.10, 95% CI: 1.03-1.17, P = 0.005) in the primary study. The results of sensitivity analyses were consistent.</AbstractText><AbstractText Label="CONCLUSIONS">Our systematic MR analyses provided suggestive evidence to support causal associations of circulating FGF-basic and IP-10 with the risk of ALS. More studies are warranted to explore how these cytokines may affect the development of ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Linshuoshuo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Wenkai</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guo-Bo</ForeName><Initials>GB</Initials><Identifier Source="ORCID">0000-0001-5475-8237</Identifier><AffiliationInfo><Affiliation>Center for General Practice Medicine, Department of General Practice Medicine, Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China. chenguobo@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. chenguobo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, 310053, China. 20191030@zcmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LY22H260005</GrantID><Agency>Natural Science Foundation of Zhejiang Province</Agency><Country/></Grant><Grant><GrantID>82174208</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Genome-wide association study</Keyword><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">Single nucleotide polymorphisms</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>0</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36737740</ArticleId><ArticleId IdType="pmc">PMC9898905</ArticleId><ArticleId IdType="doi">10.1186/s12916-023-02736-7</ArticleId><ArticleId IdType="pii">10.1186/s12916-023-02736-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E. Are professional soccer players at higher risk for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):501&#x2013;506. doi: 10.3109/21678421.2013.809764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.809764</ArticleId><ArticleId IdType="pubmed">23859483</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. 2019;59(1):10&#x2013;22. doi: 10.1002/mus.26289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74(12):1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2005;159(1-2):215&#x2013;224. doi: 10.1016/j.jneuroim.2004.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.10.009</ArticleId><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A, Larsson A, Nygren I, Blennow K, Askmark H. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. Neuroreport. 2003;14(14):1867&#x2013;1869. doi: 10.1097/00001756-200310060-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200310060-00022</ArticleId><ArticleId IdType="pubmed">14534437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilzecka J. Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2008;117(5):343&#x2013;346. doi: 10.1111/j.1600-0404.2007.00947.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2007.00947.x</ArticleId><ArticleId IdType="pubmed">17995989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16(6):771&#x2013;774. doi: 10.1111/j.1468-1331.2009.02560.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32(4):541&#x2013;544. doi: 10.1002/mus.20376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20376</ArticleId><ArticleId IdType="pubmed">15962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S. &#x2018;Mendelian randomization&#x2019;: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1&#x2013;22. doi: 10.1093/ije/dyg070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyg070</ArticleId><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925&#x2013;1926. doi: 10.1001/jama.2017.17219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.17219</ArticleId><ArticleId IdType="pubmed">29164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. doi: 10.1136/bmj.k601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k601</ArticleId><ArticleId IdType="pmc">PMC6041728</ArticleId><ArticleId IdType="pubmed">30002074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahola-Olli AV, Wurtz P, Havulinna AS, Aalto K, Pitkanen N, Lehtimaki T, et al. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genet. 2017;00(1):40&#x2013;50. doi: 10.1016/j.ajhg.2016.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.11.007</ArticleId><ArticleId IdType="pmc">PMC5223028</ArticleId><ArticleId IdType="pubmed">27989323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97(6):1268&#x2013;1283 e1266. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570&#x2013;575. doi: 10.1038/ng.610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.610</ArticleId><ArticleId IdType="pmc">PMC4615599</ArticleId><ArticleId IdType="pubmed">20562874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961&#x2013;1974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446088</ArticleId><ArticleId IdType="pubmed">27616674</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21(3):223&#x2013;242. doi: 10.1177/0962280210394459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280210394459</ArticleId><ArticleId IdType="pmc">PMC3917707</ArticleId><ArticleId IdType="pubmed">21216802</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43(3):922&#x2013;929. doi: 10.1093/ije/dyu005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyu005</ArticleId><ArticleId IdType="pmc">PMC4052137</ArticleId><ArticleId IdType="pubmed">24608958</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TM, Sterne JA, Harbord RM, Lawlor DA, Sheehan NA, Meng S, et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol. 2011;173(12):1392&#x2013;1403. doi: 10.1093/aje/kwr026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwr026</ArticleId><ArticleId IdType="pubmed">21555716</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28(1):30&#x2013;42. doi: 10.1097/EDE.0000000000000559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000559</ArticleId><ArticleId IdType="pmc">PMC5133381</ArticleId><ArticleId IdType="pubmed">27749700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44(2):512&#x2013;525. doi: 10.1093/ije/dyv080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv080</ArticleId><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693&#x2013;698. doi: 10.1038/s41588-018-0099-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS. CoStream consortium obotIGoAsP: modifiable pathways in Alzheimer&#x2019;s disease: Mendelian randomisation analysis. BMJ. 2017;359:j5375. doi: 10.1136/bmj.j5375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j5375</ArticleId><ArticleId IdType="pmc">PMC5717765</ArticleId><ArticleId IdType="pubmed">29212772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734&#x2013;1739. doi: 10.1093/ije/dyx034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyx034</ArticleId><ArticleId IdType="pmc">PMC5510723</ArticleId><ArticleId IdType="pubmed">28398548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutu DL, Galipeau J. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY) 2011;3(10):920&#x2013;933. doi: 10.18632/aging.100369.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100369</ArticleId><ArticleId IdType="pmc">PMC3229969</ArticleId><ArticleId IdType="pubmed">21990129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Zang D. Mechanism of neuroprotective effects of fibroblast growth factor 2 in the mouse model of ALS. Zhonghua Yi Xue Za Zhi. 2016;96(11):886&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">27045653</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau N, Jungnickel J, Knippenberg S, Ratzka A, Dengler R, Petri S, et al. Prolonged survival and milder impairment of motor function in the SOD1 ALS mouse model devoid of fibroblast growth factor 2. Neurobiol Dis. 2012;47(2):248&#x2013;257. doi: 10.1016/j.nbd.2012.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.04.008</ArticleId><ArticleId IdType="pubmed">22542539</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhya R, Zingg W, Shetty S, Shetty AK. Astrocyte-derived extracellular vesicles: neuroreparative properties and role in the pathogenesis of neurodegenerative disorders. J Control Release. 2020;323:225&#x2013;239. doi: 10.1016/j.jconrel.2020.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7299747</ArticleId><ArticleId IdType="pubmed">32289328</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med. 2017;7(8):a024117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22(3):121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203691</ArticleId><ArticleId IdType="pubmed">21802343</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh MY, Cho KA, Kim H, Kim SM, Kim SH. Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS) Neurosci Lett. 2014;574:53&#x2013;58. doi: 10.1016/j.neulet.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.05.001</ArticleId><ArticleId IdType="pubmed">24820540</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner C, Perner F, Stubendorff B, Forster M, Witte OW, Heidel FH, et al. Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. J Neuroinflammation. 2018;15(1):99. doi: 10.1186/s12974-018-1135-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1135-3</ArticleId><ArticleId IdType="pmc">PMC5874995</ArticleId><ArticleId IdType="pubmed">29592817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Roos PM, Larsson SC. Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(10):1913&#x2013;1917. doi: 10.1111/ene.14338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14338</ArticleId><ArticleId IdType="pubmed">32441415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang T, Han Z, Liu G. Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases. Neurol Sci. 2020;41(10):2875&#x2013;2882. doi: 10.1007/s10072-020-04381-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04381-x</ArticleId><ArticleId IdType="pubmed">32328834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung CHC, Schooling CM. Systemic inflammatory regulators and risk of Alzheimer&#x2019;s disease: a bidirectional Mendelian-randomization study. Int J Epidemiol. 2021;50(3):829&#x2013;840. doi: 10.1093/ije/dyaa241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa241</ArticleId><ArticleId IdType="pubmed">33313759</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, le Cessie S, Blauw GJ, Franceschi C, Noordam R, van Heemst D. Systemic inflammatory markers in relation to cognitive function and measures of brain atrophy: a Mendelian randomization study. Geroscience.&#xa0;2022;44(4):2259&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9616983</ArticleId><ArticleId IdType="pubmed">35689786</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103&#x2013;1116. doi: 10.1002/acn3.51078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Berry JD, Macklin EA, Beers DR, Mendoza PA, Zhao W, et al. Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(6):e200019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9423710</ArticleId><ArticleId IdType="pubmed">36038262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, McDonald TS, Fung JNT, Woodruff TM. Absence of receptor for advanced glycation end product (RAGE) reduces inflammation and extends survival in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Mol Neurobiol. 2020;57(10):4143&#x2013;4155. doi: 10.1007/s12035-020-02019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02019-9</ArticleId><ArticleId IdType="pubmed">32676989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>